DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Axelopran
Axelopran
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Mai Muuttunut Piu Miu Miui
Treatment of Opioid-Induced Constipation
Emerging Therapies for Patients with Symptoms of Opioid-Induced Bowel Dysfunction
Exploring Relief and Managing Side Effects of This Activity Issupported Byan Educationalgrant from Astrazeneca
Palliation of Opioid-Induced Constipation
PHARMACY and THERAPEUTICS COMMITTEE AGENDA Date Of
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, DC 20549
DRUG NEWS Many Consumers Exceed Safe Dosages Breaking
Peripherally Acting Mu-Opioid Antagonist for the Treatment of Opioid-Induced
Opioid Receptor Antagonist (Pamoras) for the Management of Patients with Opioid-Induced Constipation: a Systematic Review
WO 2018/005695 Al O
Drug-Induced Diseases
Peripherally Acting Μ‐Opioid Antagonist for the Treatment Of
Drug List Learning Objectives Opioids
Axelopran Phase 2B Study Demonstrates a Sustained Increase in Bowel Movement Frequency
( 12 ) United States Patent ( 10 ) Patent No .: US 10,946,009 B2 Li Et Al
PAMORAS- Peripherally Acting Mu Opioid Receptor Antagonists Medication Dosing Metabolism Clinical Significance
Top View
Il Problema Della Stipsi Nel Paziente Anziano Oncologico in Trattamento Con Oppiacei
Combating Opioid-Induced Constipation: New and Emerging Therapies
En Busca Del Opioide Ideal. Nuevas Moléculas
Stop the (Mu)Sic (Gregory)
Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at Painweek(R) 2015
Constipation in the Critically Ill Child
Managing Opioid Induced Constipation
Opioid-Induced Constipation (In Non-Cancer Pain)
Axelopran (TD-1211) Puma for Opioid-Induced Constipation
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Machine Learning Harnesses Molecular Dynamics to Discover New Μ Opioid Chemotypes